Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07789106 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07789106 · ClinicalTrials.gov record · last posted 2026-08-27

A Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists

Study acronym: Project Zest
StatusNot Yet Recruiting
PhaseNot applicable
SponsorStudySetGo
Started2026-09-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The goal of this clinical trial is to learn if a daily ubiquinol supplement can reduce fatigue and help maintain muscle strength in adults aged 30-65 who are taking a GLP-1 weight loss medication (Wegovy® or Mounjaro®). Ubiquinol is a form of Coenzyme Q10 (CoQ10), a substance the body makes naturally that plays a key role in energy production. The main questions it aims to answer are: Does ubiquinol lower fatigue levels compared to a placebo (a look-alike capsule that contains no ubiquinol)? Does ubiquinol help maintain muscle strength during weight loss treatment? Researchers will compare ubiquinol to a placebo to see if ubiquinol helps with fatigue and muscle strength in people using GLP-1 medications. Participants will: Take one ubiquinol (100 mg) or placebo capsule every day for 9 months Have a nurse visit their home 4 times (at months 0, 3, 6, and 9) to take a small blood sample, measure their body, and supervise a simple sit-to-stand exercise test Attend a short monthly video call (about 20-30 minutes) with a study dietitian Complete questionnaires and 4 days of diet logging every 3 months using a smartphone app Log all exercise sessions in the smartphone app throughout the study This is a fully remote study - participants do not need to visit a clinic. About 90 people will take part.
Trial Details
NCT Number NCT07789106
Lead Sponsor StudySetGo
Conditions Obesity & Overweight, GLP - 1, Fatigue Severity Scale, Ubiquinol, Muscle Contraction
Enrollment 90 participants
Start Date 2026-09-01
Primary Completion 2027-12-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-27